Veracyte Inc (VCYT): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Brandmark of Veracyte Corp (VCYT)

The EV/EBITDA multiple for Veracyte, Inc. (VCYT) provided by the GURU.Markets system highlights the company's breakthrough developments in RNA sequencing and transcriptomics. The 15.64 figure represents the latest metric reading, confirming a steady inflow of funds driven by the integration of tests into medical standards. The business's ultimate success relies on the precision of genomic research and the expansion of its geographic footprint.

Veracyte Corp - VCYT EV/EBITDA Multiple (period 11/23/2025 - 11/10/2026)

VCYT (veracyte.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price Veracyte Corp|VCYT - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Veracyte Diagnostics|VCYT - Business Value
- book value of equity indicators:
Book Value per Share Veracyte|VCYT - Book Capitalization|Market Value to Book Value Ratio veracyte.com|VCYT - Aggregate Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Veracyte, Inc.|VCYT - Long-Term Liabilities to Capital|Short-Term Debt to Equity Veracyte|VCYT - Company Total Debt Obligations|Debts to Book Capitalization Veracyte Diagnostics|VCYT - Long-Term Debt Volume|Company Short-Term Debt Veracyte|Quick Liquidity Indicator veracyte.com
- financial results and valuation multiples details:
VCYT - Company Net Income|Projected Future Earnings Veracyte, Inc.|VCYT - Market Cap to Earnings|Future Price to Earnings Veracyte, Inc.|VCYT - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Veracyte Diagnostics|VCYT - Operating profit EBITDA|Net earnings per share (EPS TTM) Veracyte|VCYT - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months veracyte.com|VCYT - Earnings per share growth rate in current year|Expected earnings per share growth for next year Veracyte, Inc.
Comprehensive company analysis:Veracyte Corp VCYT
Manufactured products of Veracyte

When assessing the resilience of Veracyte, Inc. (VCYT) to market downturns, it is essential to consider the high margins of Afirma and Decipher genomic tests, which minimize reliance on invasive procedures. Analyzing changes in the EV/EBITDA multiple allows for the correlation of total enterprise value with operating profit before depreciation and taxes, determining the real price of assets adjusted for debt load to identify trend reversal points.

Analysis of competing companies

EV/EBITDA Multiple CAI (Caris)|EV/EBITDA Multiple Guardant Corp GH|CELC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GRAL (grail.com) - Enterprise Value to Operating Income Before Depreciation|MYGN: EV/EBITDA Multiple|Castle Biosciences Inc (CSTL) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Burning Rock Biotech Ltd.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization VNRX|Enterprise Value to EBITDA Ratio BDSX (Biodesix, Inc.)|PRPO - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Check-Cap CHEK|Total Company Value to Operating Income Before Depreciation Ratio mainzbiomed.com (MYNZ)|OncoCyte Corp. - EV/EBITDA Multiple